AN OPEN LABEL, MULTI-CENTER, PHASE 3 STUDY WITH CORRESPONDING BLINDED IMAGE READING TO DETERMINE THE EFFICACY AND SAFETY OF A SINGLE INTRAVENOUS INJECTION OF 0.1 MMOL/KG BODY WEIGHT OF GADOBUTROL 1.0 MOLAR (GADOVIST) IN PATIENTS WITH NEWLY DIAGNOSED